RU2009149359A - Состав вакцин против менингита - Google Patents
Состав вакцин против менингита Download PDFInfo
- Publication number
- RU2009149359A RU2009149359A RU2009149359/15A RU2009149359A RU2009149359A RU 2009149359 A RU2009149359 A RU 2009149359A RU 2009149359/15 A RU2009149359/15 A RU 2009149359/15A RU 2009149359 A RU2009149359 A RU 2009149359A RU 2009149359 A RU2009149359 A RU 2009149359A
- Authority
- RU
- Russia
- Prior art keywords
- conjugate
- water
- saccharide
- influenzae
- vaccine
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 25
- 201000009906 Meningitis Diseases 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 claims abstract 45
- 241000606768 Haemophilus influenzae Species 0.000 claims abstract 28
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract 28
- 229960000814 tetanus toxoid Drugs 0.000 claims abstract 15
- 239000002671 adjuvant Substances 0.000 claims abstract 14
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims abstract 9
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract 9
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract 9
- 229940045808 haemophilus influenzae type b Drugs 0.000 claims abstract 8
- 239000012528 membrane Substances 0.000 claims abstract 6
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract 4
- 229940001442 combination vaccine Drugs 0.000 claims abstract 4
- 239000007762 w/o emulsion Substances 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 239000002775 capsule Substances 0.000 claims abstract 2
- 239000000427 antigen Substances 0.000 claims 18
- 102000036639 antigens Human genes 0.000 claims 18
- 108091007433 antigens Proteins 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 229960003983 diphtheria toxoid Drugs 0.000 claims 9
- 230000000844 anti-bacterial effect Effects 0.000 claims 7
- 241000991587 Enterovirus C Species 0.000 claims 6
- 241000700721 Hepatitis B virus Species 0.000 claims 6
- 201000005702 Pertussis Diseases 0.000 claims 6
- 230000005875 antibody response Effects 0.000 claims 5
- 239000003381 stabilizer Substances 0.000 claims 3
- 230000004044 response Effects 0.000 claims 2
- 239000002569 water oil cream Substances 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93323507P | 2007-06-04 | 2007-06-04 | |
| US60/933,235 | 2007-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009149359A true RU2009149359A (ru) | 2011-07-20 |
Family
ID=40094241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009149359/15A RU2009149359A (ru) | 2007-06-04 | 2008-06-04 | Состав вакцин против менингита |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100203137A1 (enExample) |
| EP (1) | EP2152302B1 (enExample) |
| JP (1) | JP5637848B2 (enExample) |
| CN (1) | CN101678094B (enExample) |
| AU (2) | AU2008259423A1 (enExample) |
| BR (1) | BRPI0811979A2 (enExample) |
| CA (1) | CA2688268A1 (enExample) |
| ES (1) | ES2555786T3 (enExample) |
| IN (1) | IN2009KN04098A (enExample) |
| MX (1) | MX2009013112A (enExample) |
| NZ (1) | NZ581367A (enExample) |
| RU (1) | RU2009149359A (enExample) |
| WO (1) | WO2008149238A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261350A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| EP2258851A1 (en) | 1999-05-19 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Combination neisserial compositions |
| EP1801219B1 (en) | 1999-10-29 | 2015-10-14 | GlaxoSmithKline Biologicals S.A. | Neisserial antigenic peptides |
| PT1790660E (pt) | 2000-02-28 | 2012-09-17 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
| EP2277541A1 (en) * | 2000-06-29 | 2011-01-26 | SmithKline Beecham Biologicals S.A. | Multivalent vaccine composition |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| WO2007000341A2 (en) | 2005-06-27 | 2007-01-04 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| SI2200642T1 (sl) * | 2007-10-19 | 2012-06-29 | Novartis Ag | Formulacije meningokoknega cepiva |
| NZ587382A (en) | 2008-02-21 | 2012-01-12 | Novartis Ag | Meningococcal fhbp polypeptides |
| EP2303286A4 (en) * | 2008-06-16 | 2011-12-28 | Academia Sinica | COMPOSITIONS FOR GENERATING IMMUNE REACTIONS SPECIFIC TO GLOBO H AND SSEA3 AND THEIR USES IN CANCER TREATMENT |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| ES2797504T3 (es) * | 2009-03-24 | 2020-12-02 | Glaxosmithkline Biologicals Sa | Proteína de enlace del factor H meningocócico utilizada como adyuvante |
| BRPI1009829A2 (pt) * | 2009-03-24 | 2016-11-16 | Novartis Ag | combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos |
| WO2011161653A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| SI2608805T2 (sl) | 2010-08-23 | 2025-09-30 | Wyeth Llc | Stabilne formulacije antigenov rLP2086 neisserie meningitidis |
| BR112013005329A2 (pt) | 2010-09-10 | 2017-05-02 | Wyeth Llc | variantes não lipidadas de antígenos orf2086 de neisseria meningitidis |
| AU2011338723A1 (en) * | 2010-12-10 | 2013-05-30 | Merck Sharp & Dohme Corp. | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| IN2012MU00206A (enExample) * | 2012-01-20 | 2013-08-09 | ||
| AU2013229432A1 (en) * | 2012-03-08 | 2014-10-16 | Novartis Ag | Adjuvanted formulations of booster vaccines |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MX2018011291A (es) | 2012-03-09 | 2023-01-31 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| NZ630133A (en) | 2012-06-14 | 2016-10-28 | Novartis Ag | Vaccines for serogroup x meningococcus |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| AU2017321863B2 (en) | 2016-09-02 | 2024-07-11 | Sanofi Pasteur, Inc. | Neisseria meningitidis vaccine |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| EP0658118B1 (en) | 1992-08-31 | 2002-01-23 | Baxter Healthcare S.A. | Vaccines against group c neisseria meningitidis |
| US5425946A (en) | 1992-08-31 | 1995-06-20 | North American Vaccine, Inc. | Vaccines against group C Neisseria meningitidis |
| GB9422096D0 (en) * | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| JP4850987B2 (ja) | 1995-06-23 | 2012-01-11 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物 |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| EP2277541A1 (en) | 2000-06-29 | 2011-01-26 | SmithKline Beecham Biologicals S.A. | Multivalent vaccine composition |
| EP1355673B1 (en) | 2001-01-23 | 2012-05-30 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| BR0308768A (pt) | 2002-03-26 | 2005-02-15 | Chiron Srl | Sacarìdeos modificados possuindo estabilidade melhorada em água |
| PT2191844E (pt) * | 2003-01-30 | 2014-06-04 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| RU2378010C2 (ru) | 2003-10-02 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс С.Р.Л. | Жидкие вакцины для множественных серогрупп менингококков |
| GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
| GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| CN1709505B (zh) * | 2005-07-13 | 2010-06-16 | 北京绿竹生物制药有限公司 | 多价细菌荚膜多糖-蛋白质结合物联合疫苗 |
| BRPI0615420A2 (pt) * | 2005-09-01 | 2011-05-17 | Novartis Vaccines & Diagnostic | vacinação múltipla que inclui meningococo do sorogrupo c |
| GB0524066D0 (en) * | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| SI2200642T1 (sl) * | 2007-10-19 | 2012-06-29 | Novartis Ag | Formulacije meningokoknega cepiva |
-
2008
- 2008-06-04 NZ NZ581367A patent/NZ581367A/en not_active IP Right Cessation
- 2008-06-04 CA CA2688268A patent/CA2688268A1/en not_active Abandoned
- 2008-06-04 BR BRPI0811979-1A2A patent/BRPI0811979A2/pt not_active IP Right Cessation
- 2008-06-04 IN IN4098KON2009 patent/IN2009KN04098A/en unknown
- 2008-06-04 EP EP08789070.3A patent/EP2152302B1/en active Active
- 2008-06-04 ES ES08789070.3T patent/ES2555786T3/es active Active
- 2008-06-04 US US12/451,831 patent/US20100203137A1/en not_active Abandoned
- 2008-06-04 JP JP2010510910A patent/JP5637848B2/ja not_active Expired - Fee Related
- 2008-06-04 RU RU2009149359/15A patent/RU2009149359A/ru not_active Application Discontinuation
- 2008-06-04 MX MX2009013112A patent/MX2009013112A/es active IP Right Grant
- 2008-06-04 WO PCT/IB2008/002121 patent/WO2008149238A2/en not_active Ceased
- 2008-06-04 AU AU2008259423A patent/AU2008259423A1/en not_active Abandoned
- 2008-06-04 CN CN200880018507.2A patent/CN101678094B/zh not_active Expired - Fee Related
-
2014
- 2014-07-15 AU AU2014204425A patent/AU2014204425B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2555786T3 (es) | 2016-01-08 |
| CN101678094B (zh) | 2014-08-27 |
| JP2010529103A (ja) | 2010-08-26 |
| AU2014204425B2 (en) | 2015-10-29 |
| EP2152302A2 (en) | 2010-02-17 |
| IN2009KN04098A (enExample) | 2015-08-28 |
| AU2014204425A1 (en) | 2014-08-07 |
| CN101678094A (zh) | 2010-03-24 |
| MX2009013112A (es) | 2010-03-01 |
| EP2152302B1 (en) | 2015-10-07 |
| US20100203137A1 (en) | 2010-08-12 |
| CA2688268A1 (en) | 2008-12-11 |
| AU2008259423A1 (en) | 2008-12-11 |
| JP5637848B2 (ja) | 2014-12-10 |
| WO2008149238A2 (en) | 2008-12-11 |
| NZ581367A (en) | 2012-05-25 |
| WO2008149238A3 (en) | 2009-08-06 |
| BRPI0811979A2 (pt) | 2014-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009149359A (ru) | Состав вакцин против менингита | |
| US11135279B2 (en) | Immunogenic compositions for use in pneumococcal vaccines | |
| RU2006142156A (ru) | Объединенные менингококковые конъюгаты с общим белком-носителем | |
| RU2009134033A (ru) | Жидкие вакцины для множественных серогрупп менингококков | |
| JP5346308B2 (ja) | ワクチン組成物 | |
| RU2008112289A (ru) | Множественная вакцинация, включающая менингококки серогруппы с | |
| JP2004501873A5 (enExample) | ||
| RU2009108660A (ru) | Вакцины на основе солюбилизированных и комбинированных капсулярных полисахаридов | |
| RU2004136299A (ru) | Мукозальные вакцины с хитозановым адъювантом и/или антигенами менингококков | |
| JP2014506916A5 (enExample) | ||
| JP2009525260A5 (enExample) | ||
| RU2007130774A (ru) | Вакцинация менингококковыми конъюгатами | |
| CZ418997A3 (cs) | Kombinovaná vakcína, souprava, která ji obsahuje a způsob výroby této vakcíny | |
| JP2014218516A5 (enExample) | ||
| JP2018115159A (ja) | 肺炎球菌ワクチンにおいて用いるための免疫原性組成物 | |
| RU2011142774A (ru) | Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов | |
| CN105267974A (zh) | 用于缀合疫苗的经过修饰的多糖 | |
| RU2010119947A (ru) | Составы менингококковых вакцин | |
| RU2006142158A (ru) | Вакцинация менингококковыми конъюгатами | |
| JP2006528936A5 (enExample) | ||
| RU2007138492A (ru) | Комбинированные вакцины с антигеном коклюша цельных клеток | |
| PL174130B1 (pl) | Złożona szczepionka pediatryczna przeciwko błonicy, tężcowi, ksztuścowi oraz Haemophilus influenzae typu b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130826 |